|
1
|
Benson AB, Venook AP, Al-Hawary MM, Arain
MA, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D,
Garrido-Laguna I, et al: NCCN guidelines insights: Rectal cancer,
version 6.2020. J Natl Compr Canc Netw. 18:806–815. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Benson AB, Venook AP, Al-Hawary MM, Azad
N, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D,
Garrido-Laguna I, et al: Rectal cancer, version 2.2022, NCCN
clinical practice guidelines in oncology. J Natl Compr Canc Netw.
20:1139–1167. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang X, Ma S, Guo Y, Luo Y and Li L:
Total neoadjuvant therapy versus standard therapy in locally
advanced rectal cancer: A systematic review and meta-analysis of 15
trials. PLoS One. 17:e02765992022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhao JY, Tang QQ, Luo YT, Wang SM, Zhu XR
and Wang XY: Predictive value of a serum tumor biomarkers scoring
system for clinical stage II/III rectal cancer with neoadjuvant
chemoradiotherapy. World J Gastrointest Oncol. 14:2014–2024. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Donnelly M, Ryan OK, Ryan ÉJ, Creavin B,
O'Reilly M, McDermott R, Kennelly R, Hanly A, Martin ST and Winter
DC: Total neoadjuvant therapy versus standard neoadjuvant treatment
strategies for the management of locally advanced rectal cancer:
Network meta-analysis of randomized clinical trials. Br J Surg.
110:1316–1330. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhu J, Lian J, Xu B, Pang X, Ji S, Zhao Y
and Lu H: Neoadjuvant immunotherapy for colorectal cancer: Right
regimens, right patients, right directions? Front Immunol.
14:11206842023. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Guida A, Sensi B, Formica V, D'Angelillo
R, Roselli M, Del Vecchio Blanco G, Rossi P, Capolupo GT, Caricato
M and Sica GS: Total neoadjuvant therapy for the treatment of
locally advanced rectal cancer: A systematic minireview. Biol
Direct. 17:162022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Marco MR, Zhou L, Patil S, Marcet JE,
Varma MG, Oommen S, Cataldo PA, Hunt SR, Kumar A, Herzig DO, et al:
Consolidation mFOLFOX6 chemotherapy after chemoradiotherapy
improves survival in patients with locally advanced rectal cancer:
Final results of a multicenter phase II trial. Dis Colon Rectum.
61:1146–1155. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Garcia-Aguilar J, Patil S, Gollub MJ, Kim
JK, Yuval JB, Thompson HM, Verheij FS, Omer DM, Lee M, Dunne RF, et
al: Organ preservation in patients with rectal adenocarcinoma
treated with total neoadjuvant therapy. J Clin Oncol. 40:2546–2556.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bauer PS, Chapman WC Jr, Atallah C,
Makhdoom BA, Damle A, Smith RK, Wise PE, Glasgow SC, Silviera ML,
Hunt SR and Mutch MG: Perioperative complications after proctectomy
for rectal cancer: Does neoadjuvant regimen matter? Ann Surg.
275:e428–e432. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Petrelli F, Trevisan F, Cabiddu M, Sgroi
G, Bruschieri L, Rausa E, Ghidini M and Turati L: Total neoadjuvant
therapy in rectal cancer: A systematic review and meta-analysis of
treatment outcomes. Ann Surg. 271:440–448. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gago T, Caldeira P, Cunha AC, Campelo P
and Guerreiro H: Can we optimize CEA as a response marker in rectal
cancer? Rev Esp Enferm Dig. 113:423–428. 2021.PubMed/NCBI
|
|
13
|
Cheong C, Shin JS and Suh KW: Prognostic
value of changes in serum carcinoembryonic antigen levels for
preoperative chemoradiotherapy response in locally advanced rectal
cancer. World J Gastroenterol. 26:7022–7035. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li B, Han J, Wang F, Yu B, Wang G and Yang
F: Factors affecting survival prognosis of patients with rectal
cancer after neoadjuvant chemoradiotherapy. Front Oncol.
15:15626342025. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Morais M, Fonseca T, Machado-Neves R,
Honavar M, Coelho AR, Lopes J, Barbosa E, Guerreiro E and Carneiro
S: Can pretreatment blood biomarkers predict pathological response
to neoadjuvant chemoradiotherapy in patients with locally advanced
rectal cancer? Front Oncol. 17:4947–4957. 2021.
|
|
16
|
Sun GW, Shook TL and Kay GL: Inappropriate
use of bivariable analysis to screen risk factors for use in
multivariable analysis. J Clin Epidemiol. 49:907–916. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Beauchemin N and Arabzadeh A:
Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs)
in cancer progression and metastasis. Cancer Metastasis Rev.
32:643–671. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen Y, Liu D, Wang Z, Lin Y, Jiang X, Liu
J and Lian L: Machine learning-based dynamic CEA trajectory and
prognosis in gastric cancer. BMC Cancer. 25:12212025. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kau SY, Shyr YM, Su CH, Wu CW and Lui WY:
Diagnostic and prognostic values of CA 19-9 and CEA in
periampullary cancers. J Am Coll Surg. 188:415–420. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bast RC Jr, Ravdin P, Hayes DF, Bates S,
Fritsche H Jr, Jessup JM, Kemeny N, Locker GY, Mennel RG and
Somerfield MR; American Society of Clinical Oncology Tumor Markers
Expert Panel, : 2000 update of recommendations for the use of tumor
markers in breast and colorectal cancer: Clinical practice
guidelines of the American society of clinical oncology. J Clin
Oncol. 19:1865–1878. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Vogel JD, Felder SI, Bhama AR, Hawkins AT,
Langenfeld SJ, Shaffer VO, Thorsen AJ, Weiser MR, Chang GJ,
Lightner AL, et al: The American society of colon and rectal
surgeons clinical practice guidelines for the management of colon
cancer. Dis Colon Rectum. 65:148–177. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
You YN, Hardiman KM, Bafford A, Poylin V,
Francone TD, Davis K, Paquette IM, Steele SR and Feingold DL: On
Behalf of the Clinical Practice Guidelines Committee of the
American Society of Colon Rectal Surgeons: The American society of
colon and rectal surgeons clinical practice guidelines for the
management of rectal cancer. Dis Colon Rectum. 63:1191–1222. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dowaki S, Kijima H, Kashiwagi H, Ohtani Y,
Tobita K, Tsukui M, Tanaka Y, Tazawa K, Matsubayashi H, Tsuchida T,
et al: CEA immunohistochemical localization is correlated with
growth and metastasis of human gallbladder carcinoma. Int J Oncol.
16:49–53. 2000.PubMed/NCBI
|
|
24
|
Kijima H, Oshiba G, Kenmochi T, Kise Y,
Tanaka H, Chino O, Shimada H, Ueyama Y, Tanaka M and Makuuchi H:
Stromal CEA immunoreactivity is correlated with lymphatic invasion
of human esophageal carcinoma. Int J Oncol. 16:677–681.
2000.PubMed/NCBI
|
|
25
|
Reinert T, Henriksen TV, Christensen E,
Sharma S, Salari R, Sethi H, Knudsen M, Nordentoft I, Wu HT, Tin
AS, et al: Analysis of plasma cell-free DNA by ultradeep sequencing
in patients with stages I to III colorectal cancer. JAMA Oncol.
5:1124–1131. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mo S, Ye L, Wang D, Han L, Zhou S, Wang H,
Dai W, Wang Y, Luo W, Wang R, et al: Early detection of molecular
residual disease and risk stratification for stage I to III
colorectal cancer via circulating tumor DNA methylation. JAMA
Oncol. 9:770–778. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Henriksen TV, Tarazona N, Frydendahl A,
Reinert T, Gimeno-Valiente F, Carbonell-Asins JA, Sharma S, Renner
D, Hafez D, Roda D, et al: Circulating tumor DNA in stage III
colorectal cancer, beyond minimal residual disease detection,
toward assessment of adjuvant therapy efficacy and clinical
behavior of recurrences. Clin Cancer Res. 28:507–517. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jeong S, Nam TK, Jeong JU, Kim SH, Kim K,
Jang HS, Jeong BK and Lee JH: Postoperative carcinoembryonic
antigen level has a prognostic value for distant metastasis and
survival in rectal cancer patients who receive preoperative
chemoradiotherapy and curative surgery: A retrospective
multi-institutional analysis. Clin Exp Metastasis. 33:809–816.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Al-Masri M, Safi Y, Almasri M, Kardan R,
Mustafa D, Alayyan O, Kahalah B and AlMasri R: Prognostic value of
dynamic changes in immune-inflammatory and tumor biomarkers
following chemoradiotherapy in locally advanced rectal cancer.
Cancers (Basel). 17:33832025. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ning S, Wei W, Li J, Hou B, Zhong J, Xie
Y, Liu H, Mo X, Chen J and Zhang L: Clinical significance and
diagnostic capacity of serum TK1, CEA, CA 19-9 and CA 72-4 levels
in gastric and colorectal cancer patients. J Cancer. 9:494–501.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xie H, Wei L, Wang Q, Tang S and Gan J:
Grading carcinoembryonic antigen levels can enhance the
effectiveness of prognostic stratification in patients with
colorectal cancer: A single-centre retrospective study. BMJ Open.
14:e0842192024. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zahorec R: Neutrophil-to-lymphocyte ratio,
past, present and future perspectives. Bratisl Lek Listy.
122:474–488. 2021.PubMed/NCBI
|
|
33
|
Zheng X, Zhou L, Shi H, An J, Xu W, Ding
X, Hua Y, Shi W and Li X: Immune-inflammatory markers and clinical
characteristics as predictors of the depth of response and
prognosis of patients with PD-L1 ≥50% metastatic non-small cell
lung cancer receiving first-line immunotherapy. Thorac Cancer.
15:2029–2037. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li F, Wang Y, Dou H, Chen X, Wang J and
Xiao M: Association of immune inflammatory biomarkers with
pathological complete response and clinical prognosis in young
breast cancer patients undergoing neoadjuvant chemotherapy. Front
Oncol. 14:13490212024. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chen Q, Zhai B, Li J, Wang H, Liu Z, Shi
R, Wu H, Xu Y and Ji S: Systemic immune-inflammatory index predict
short-term outcome in recurrent/metastatic and locally advanced
cervical cancer patients treated with PD-1 inhibitor. Sci Rep.
14:315282024. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Szczerba BM, Castro-Giner F, Vetter M,
Krol I, Gkountela S, Landin J, Scheidmann MC, Donato C, Scherrer R,
Singer J, et al: Neutrophils escort circulating tumour cells to
enable cell cycle progression. Nature. 566:553–557. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cristinziano L, Modestino L, Antonelli A,
Marone G, Simon HU, Varricchi G and Galdiero MR: Neutrophil
extracellular traps in cancer. Semin Cancer Biol. 79:91–104. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Coffelt SB, Kersten K, Doornebal CW,
Weiden J, Vrijland K, Hau CS, Verstegen NJM, Ciampricotti M,
Hawinkels LJAC, Jonkers J and de Visser KE: IL-17-producing γδ T
cells and neutrophils conspire to promote breast cancer metastasis.
Nature. 522:345–348. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Huang CX, Lao XM, Wang XY, Ren YZ, Lu YT,
Shi W, Wang YZ, Wu CY, Xu L, Chen MS, et al: Pericancerous
cross-presentation to cytotoxic T lymphocytes impairs
immunotherapeutic efficacy in hepatocellular carcinoma. Cancer
Cell. 42:2082–2097.e10. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Grisaru-Tal S, Itan M, Klion AD and Munitz
A: A new dawn for eosinophils in the tumour microenvironment. Nat
Rev Cancer. 20:594–607. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ding Y, Chen Y, Zhang J, Wang Q, Zhu S,
Jiang J, He C, Wang J, Tou L, Zheng J, et al: Blood biomarker-based
predictive indicator for liver metastasis in
alpha-fetoprotein-producing gastric cancer and multi-omics tumor
microenvironment insights. Adv Sci (Weinh). 12:e034992025.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Amin MB, Greene FL, Edge SB, Compton CC,
Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR and
Winchester DP: The eighth edition AJCC cancer staging manual:
Continuing to build a bridge from a population-based to a more
‘personalized’ approach to cancer staging. CA Cancer J Clin.
67:93–99. 2017.PubMed/NCBI
|
|
43
|
Ganesh K, Stadler ZK, Cercek A, Mendelsohn
RB, Shia J, Segal NH and Diaz LA Jr: Immunotherapy in colorectal
cancer: Rationale, challenges and potential. Nat Rev Gastroenterol
Hepatol. 16:361–375. 2019. View Article : Google Scholar : PubMed/NCBI
|
